Krister Wennerberg

19.1k total citations · 5 hit papers
153 papers, 10.5k citations indexed

About

Krister Wennerberg is a scholar working on Molecular Biology, Computational Theory and Mathematics and Oncology. According to data from OpenAlex, Krister Wennerberg has authored 153 papers receiving a total of 10.5k indexed citations (citations by other indexed papers that have themselves been cited), including 96 papers in Molecular Biology, 33 papers in Computational Theory and Mathematics and 30 papers in Oncology. Recurrent topics in Krister Wennerberg's work include Computational Drug Discovery Methods (33 papers), Bioinformatics and Genomic Networks (21 papers) and Cancer Genomics and Diagnostics (17 papers). Krister Wennerberg is often cited by papers focused on Computational Drug Discovery Methods (33 papers), Bioinformatics and Genomic Networks (21 papers) and Cancer Genomics and Diagnostics (17 papers). Krister Wennerberg collaborates with scholars based in Finland, Denmark and United States. Krister Wennerberg's co-authors include Keith Burridge, Channing J. Der, Tero Aittokallio, Kent L. Rossman, Jing Tang, Bhagwan Yadav, Shawn M. Ellerbroek, Kris A. DeMali, William T. Arthur and Staffan Johansson and has published in prestigious journals such as Nature, Cell and Nucleic Acids Research.

In The Last Decade

Krister Wennerberg

148 papers receiving 10.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Rho and Rac Take Center Stage

2004 1.5k citations Keith Burridge, Krister Wennerberg profile →
The Ras superfamily at a glance

2005 1.1k citations Krister Wennerberg, Channing J. Der et al. profile →
Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model

2015 506 citations Bhagwan Yadav, Krister Wennerberg et al. profile →
Making Sense of Large-Scale Kinase Inhibitor Bioactivity Data Sets: A Comparative and Integrative Analysis

2014 377 citations Jing Tang, Krister Wennerberg et al. profile →
Network pharmacology applications to map the unexplored target space and therapeutic potential of natural products

2015 346 citations Jing Tang, Krister Wennerberg et al. profile →

Peers

Countries citing papers authored by Krister Wennerberg

Since Specialization

Citations

This map shows the geographic impact of Krister Wennerberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Krister Wennerberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Krister Wennerberg more than expected).

Fields of papers citing papers by Krister Wennerberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Krister Wennerberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Krister Wennerberg. The network helps show where Krister Wennerberg may publish in the future.

Co-authorship network of co-authors of Krister Wennerberg

This figure shows the co-authorship network connecting the top 25 collaborators of Krister Wennerberg. A scholar is included among the top collaborators of Krister Wennerberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Krister Wennerberg. Krister Wennerberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Machine Learning–Based Strategy Predicts Selective and Synergistic Drug Combinations for Relapsed Acute Myeloid Leukemia 2025 ·Cancer Research ·Yingjia Chen, Liye He, Aleksandr Ianevski, (unknown), Tanja Ruokoranta, (unknown), Juho J. Miettinen, Markus Vähä‐Koskela, (unknown), Heikki Kuusanmäki, Mika Kontro, Kimmo Porkka, Krister Wennerberg, Caroline A. Heckman, Anil K. Giri, Tero Aittokallio	4
2	Single-cell transcriptomes identify patient-tailored therapies for selective co-inhibition of cancer clones 2024 ·Nature Communications ·Aleksandr Ianevski, (unknown), (unknown), Wojciech Senkowski, Daria Bulanova, Lidia Moyano‐Galceran, Tanja Ruokoranta, Heikki Kuusanmäki, (unknown), (unknown), Markus Vähä‐Koskela, Anil K. Giri, Anna Vähärautio, Mika Kontro, Kimmo Porkka, Esa Pitkänen, Caroline A. Heckman, Krister Wennerberg, Tero Aittokallio	13
3	Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidine 2024 ·Cell Death and Disease ·(unknown), (unknown), Mette C. Kriegbaum, (unknown), (unknown), Markus Vähä‐Koskela, Mika Kontro, Krister Wennerberg, Caroline A. Heckman	5
4	GDNF/GFRA1 signaling contributes to chemo- and radioresistance in glioblastoma 2024 ·Scientific Reports ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Mark Burton, Mads Thomassen, Krister Wennerberg, Signe Regner Michaelsen, Bjarne Winther Kristensen	4
5	Standardized assays to monitor drug sensitivity in hematologic cancers 2023 ·Cell Death Discovery ·(unknown), (unknown), (unknown), (unknown), (unknown), Sandra Gordon, Heikki Kuusanmäki, (unknown), (unknown), Kjetil Taskén, Krister Wennerberg, Jorrit M. Enserink, Sigrid S. Skånland	11
6	Minimal information for chemosensitivity assays (MICHA): a next-generation pipeline to enable the FAIRification of drug screening experiments 2021 ·Briefings in Bioinformatics ·Ziaurrehman Tanoli, Jehad Aldahdooh, (unknown), Yinyin Wang, (unknown), Maddalena Fratelli, (unknown), Marián Hajdúch, Florence Biétrix, Philip Gribbon, Andrea Zaliani, Matthew D. Hall, Min Shen, Kyle R. Brimacombe, Evgeny Kulesskiy, Jani Saarela, Krister Wennerberg, Markus Vähä‐Koskela, Jing Tang	8
7	Patient-tailored design for selective co-inhibition of leukemic cell subpopulations 2021 ·Science Advances ·Aleksandr Ianevski, Jenni Lahtela, Komal Kumar Javarappa, (unknown), Bishwa Ghimire, Prson Gautam, Markus Vähä‐Koskela, Laura Turunen, (unknown), Heikki Kuusanmäki, Mika Kontro, Kimmo Porkka, Caroline A. Heckman, Pirkko Mattila, Krister Wennerberg, Anil K. Giri, Tero Aittokallio	27
8	Therapeutic targeting of KSP in preclinical models of high-risk neuroblastoma 2020 ·Science Translational Medicine ·Karin Hansson, (unknown), Kristina Aaltonen, Jani Saarela, (unknown), Jonas Sjölund, Emma Smith, Kristian Pietras, Sven Påhlman, Krister Wennerberg, David Gisselsson, Daniel Bexell	22
9	Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify Kras -Mutant Lung Cancers 2019 ·Molecular Cancer Therapeutics ·(unknown), Ashwini S. Nagaraj, Jennifer R. Devlin, Annabrita Hemmes, Swapnil Potdar, Elina A. Kiss, Pipsa Saharinen, Kaisa Salmenkivi, Mikko I. Mäyränpää, Krister Wennerberg, Emmy W. Verschuren	5
10	Prediction of drug combination effects with a minimal set of experiments 2019 ·Nature Machine Intelligence ·Aleksandr Ianevski, Anil K. Giri, Prson Gautam, Alexander Kononov, Swapnil Potdar, Jani Saarela, Krister Wennerberg, Tero Aittokallio	106
11	Anagrelide for Gastrointestinal Stromal Tumor 2018 ·Clinical Cancer Research ·(unknown), Yemarshet K. Gebreyohannes, Agnieszka Woźniak, (unknown), Olli Tynninen, (unknown), Alejandra Cervera, Salla Keskitalo, Astrid Murumägi, Evgeny Kulesskiy, (unknown), Krister Wennerberg, Markku Varjosalo, Pirjo Laakkonen, Rainer Lehtonen, Sampsa Hautaniemi, Olli Kallioniemi, Patrick Schöffski, Harri Sihto, Heikki Joensuu	19
12	Drug-Sensitivity Screening and Genomic Characterization of 45 HPV-Negative Head and Neck Carcinoma Cell Lines for Novel Biomarkers of Drug Efficacy 2018 ·Molecular Cancer Therapeutics ·(unknown), (unknown), Riku Louhimo, Bhagwan Yadav, Astrid Murumägi, Evgeny Kulesskiy, (unknown), Harri Sihto, Reidar Grénman, Stina Syrjänen, Olli Kallioniemi, Tero Aittokallio, Krister Wennerberg, Heikki Joensuu, Outi Monni	32
13	Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients 2018 ·Cancer Research ·Liye He, Jing Tang, Emma Andersson, Sanna Timonen, Steffen Koschmieder, Krister Wennerberg, Satu Mustjoki, Tero Aittokallio	55
14	Toward universal protein post-translational modification detection in high throughput format 2018 ·Chemical Communications ·Harri Härmä, (unknown), Arjan J. van Adrichem, Ilian Jelesarov, Krister Wennerberg, Kari Kopra	10
15	Drug Target Commons 2.0: a community platform for systematic analysis of drug–target interaction profiles 2018 ·Database ·Ziaurrehman Tanoli, (unknown), Markus Vähä‐Koskela, Balaguru Ravikumar, Alina Malyutina, Alok Jaiswal, Jing Tang, Krister Wennerberg, Tero Aittokallio	47
16	TIMMA-R: an R package for predicting synergistic multi-targeted drug combinations in cancer cell lines or patient-derived samples 2015 ·Bioinformatics ·Liye He, Krister Wennerberg, Tero Aittokallio, Jing Tang	11
17	Bioluminescent, Nonlytic, Real-Time Cell Viability Assay and Use in Inhibitor Screening 2015 ·Assay and Drug Development Technologies ·Sarah Duellman, Wenhui Zhou, Poncho Meisenheimer, Gediminas Vidugiris, James J. Cali, Prson Gautam, Krister Wennerberg, Jolanta Vidugirienė	52
18	Bioluminescent Cell-Based NAD(P)/NAD(P)H Assays for Rapid Dinucleotide Measurement and Inhibitor Screening 2014 ·Assay and Drug Development Technologies ·Jolanta Vidugirienė, Donna Leippe, (unknown), Gediminas Vidugiris, Wenhui Zhou, Poncho Meisenheimer, Prson Gautam, Krister Wennerberg, James J. Cali	27
19	Analysis of Activated GAPs and GEFs in Cell Lysates 2006 ·Methods in enzymology on CD-ROM/Methods in enzymology ·Rafael García‐Mata, Krister Wennerberg, William T. Arthur, Nicole Noren Hooten, Shawn M. Ellerbroek, Keith Burridge	163
20	SGEF, a RhoG Guanine Nucleotide Exchange Factor that Stimulates Macropinocytosis 2004 ·Molecular Biology of the Cell ·Shawn M. Ellerbroek, Krister Wennerberg, William T. Arthur, Jill Dunty, (unknown), Kris A. DeMali, Channing J. Der, Keith Burridge	91

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact